The Anatomic and Functional Outcomes of Ozurdex-Aided Vitrectomy in Proliferative Diabetic Retinopathy
Manqiao Wang,Rong Luan,Boshi Liu,Yi Gong,Jinzhi Zhao,Xiteng Chen,Qianhui Yang,Jingjie Liu,Juping Liu,Yan Shao,Xiaorong Li
DOI: https://doi.org/10.2147/dmso.s445607
2024-03-08
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Manqiao Wang, &ast Rong Luan, &ast Boshi Liu, Yi Gong, Jinzhi Zhao, Xiteng Chen, Qianhui Yang, Jingjie Liu, Juping Liu, Yan Shao, Xiaorong Li Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yan Shao; Xiaorong Li, Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, People's Republic of China, Tel +86 17622651170; +86 18622818042, Email ; Purpose: To investigate the 3-months outcomes of patients who underwent intraoperative intravitreal injection of Ozurdex for proliferative diabetic retinopathy (PDR). Methods: This is a prospective randomized controlled clinical trial (ChiCTR2100043399). Seventy-one patients with PDR who had indications for surgery without intravitreal injection history within 3 months preoperatively were enrolled. Patients were randomly divided into three groups based on the medicine injected intraoperatively: Ozurdex, Conbercept, and Control group. The primary outcome is the best-corrected visual acuity (BCVA) within 3 months postoperatively. The secondary outcomes include the intraocular pressure (IOP), mean sensitivity, central retinal thickness and vessels perfusion. Results: The BCVA and the mean sensitivity improved in the three groups (F = 130.8, P < 0.0001; F = 34.18, P 0.05). Conclusion: Compared with the other two groups, anatomical outcomes was improved significantly in Ozurdex group for DR patients. Ozurdex may help to improve the visual acuity and visual sensitivity, and there is no significant difference in the change of IOP and microvascular improvement. Clinical Trial Registration: This trial is registered with the Chinese Clinical Trial Registry ( http://www.chictr.org.cn , registration number ChiCTR2100043399). Keywords: proliferative diabetic retinopathy, ozurdex, pars plana vitrectomy, optical coherence tomography angiography, microperimetry Diabetic retinopathy (DR) is a common and specific complication of diabetes. According to statistics, about 34.6% of diabetic patients worldwide suffer from retinopathy, of which 30% are vision threatening. 1 At present, it is believed that the early changes of DR are mainly caused by high glucose and microvascular changes, inflammatory factors, and retinal neurodegeneration. 2 Clinically, DR can be divided into proliferative and non-proliferative diabetic retinopathy according to whether there is retinal hemorrhage and neovascularization in patients' fundus. Proliferative diabetic retinopathy (PDR) mainly showed optic disc or other parts neovascularization, preretinal hemorrhage, or vitreous hemorrhage. 3 Vitrectomy should be considered for PDR patients with vitreous hemorrhage that interfere with vision. 1 For the pathological changes of DR, the use of anti-VEGF drugs or anti-inflammatory drugs after vitrectomy may reduce postoperative bleeding, relieve diabetic macular edema (DME), and help postoperative recovery. 2,4,5 Meanwhile, the study found that vitreous inflammatory cytokines and chemokines could not be reduced effectively by Conbercept, but may lead to early postoperative macular edema (ME) in patients with PDR. 6 Ozurdex (0.7mg, Dexamethasone intravitreal implant, Allergan Pharmaceuticals Ireland), as a dexamethasone sustained-release agent, has become a second-line drug for the treatment of DME. The maximum benefit occurs 2–3 months after injection, and the therapeutic effect can be maintained for up to 6 months in the human eye. 4 Many clinical trials in DME showed t -Abstract Truncated-
endocrinology & metabolism